The authors analyzed the outcome of 349 patients with primary or secondary myelofibrosis undergoing reduced intensity transplantation, of whom 35 had accelerated-phase myelofibrosis. After a median follow-up of 5.9 years, estimated 5-year overall survival was between the two groups, and median overall survival was not reached. In terms of relapse, five-year incidence was 30% for the accelerated-phase group versus 15% for the chronic-phase group. Reduced intensity transplantation showed excellent survival but higher relapse for accelerated-phase myelofibrosis.

Chemoradiotherapy with high-dose cisplatin every three weeks is the standard adjuvant treatment for patients with locally advanced squamous cell carcinoma of the head and neck with high risk for recurrence. However, the cisplatin dose is frequently reduced because of dose-related toxicities which can result in insufficient cisplatin delivery. Chemoradiotherapy with weekly cisplatin at a dose of 40 mg/m2 is widely used as a possible alternative, albeit without sufficient evidence. This clinical trial was conducted to prove the noninferiority of weekly cisplatin to three weekly cisplatin plus radiation therapy (RT).

Outcomes from the large PETHEMA registry study shows that secondary AML is common (27% of AML cases) and has a median OS of 5.6 months vs. 10.9 months for primary AML, and has various differing characteristics compared to primary AML. These include older age at diagnosis, more high-risk cytogenetics, less FMS-like tyrosine kinase three internal tandem duplication, fewer NPM1 mutations, and received a lower intensity of chemotherapy.

This quiz tests your knowledge on the appropriate screening follow-up from a 23-year-old woman who was treated for gonococcal arthritis. After a physical exam that showed a complete resolution of symptoms, which screening test is the next course of action? A CD4 lymphocyte subset? Serum IgA level? Total hemolytic complement (CH50) level? Is any additional testing even needed?

Of the nearly 83,000 mammograms taken among nearly 36,000 women screened, 1 in 7 cases was determined to be overdiagnosed. The information revealed in this Annals of Internal Medicine study clarifies the risk for breast cancer overdiagnosis in contemporary screening practice and should facilitate shared and informed decision making about mammography screening.

Published in its entirety in the Journal of the American Geriatrics Society and available here from Guideline Central, the AGS Beers Criteria® also includes a host of resources— from mobile apps to a pocket reference card. The five lists included describe particular medications with evidence suggesting they should be avoided, used in caution, or dosed differently.